Septic Shock, Lipopolysaccharide (LPS)-Induced, Rat
CONTACT CUSTOMER SERVICE
ADD TO FAVORITES
ADD TO PANEL
OVERVIEW
DOCUMENTS/REFERENCES
BIOLOGICAL INFORMATION
BACKGROUND INFORMATION
Lipopolysaccharide (LPS), a glycoprotein from gram negative bacteria, activates innate immunity through toll-like receptor 4 (TLR4). Experimental LPS-induced sepsis model is commonly used to study the mechanisms of inflammation and mortality for septic shock.
ORGANISM
Rat
ASSAY INFORMATION
ASSAY TYPE
In Vivo
TESTING INFORMATION
PROCEDURE SUMMARY
Test article is administered orally (PO) to a group of 10 Sprague Dawley (SD) rats weighing 220 ± 20 g one hour before challenge with E. Coli lipopolysaccharide (LPS, 20 mg/kg, 10 mL/kg IV; Escherichia coli. O55:B5) resulting in 80-100% mortality. Mortality is recorded over a 3-day period. Additional analyses that can be requested include cell populations by FACS, biomarker analysis (protein and/or mRNA) and histopathology etc. Suggested Testing: n=10/group (study design dependent). Doses may be administered PO, IV, IP and SC.
CRITERIA FOR SIGNIFICANCE
p<0.05 compared to vehicle control is considered significant activity
TURNAROUND TIME
STANDARD
20 Days
CLINICAL RELEVANCE
THERAPEUTIC AREA
Inflammation/Allergy
ADDITIONAL INFORMATION
BRAND
PDS
TESTING LOCATION
Taiwan - Taipei
OTHER INFORMATION
We will readily accommodate client-specified alterations. These studies are performed at our AAALAC accredited BSL-2 laboratory in Taipei, Taiwan. All aspects of this work are performed in general accordance with the Guide for the Care and Use of laboratory animals (National Academy Press, Washington, DC, 2011). The study protocol was approved by the Pharmacology Discovery Services IACUC and is performed with the oversight of veterinarians to assure the humane treatment of laboratory animals.
ITEM DOES NOT EXIST
© Copyright 2026, Pharmacology Discovery Services – Privacy Policy | Cookie Notice | Cookie Preferences